Ethanol → (4-{[5-Nitro-2-(3-piperidin-1-yl-benzylamino)-pyrimidin-4-ylamino]-methyl}-cyclohexyl)-carbamic acid tert-butyl ester
반응식
[C:1]([O:5][C:6](=[O:26])[NH:7][C@H:8]1[CH2:13][CH2:12][C@H:11]([CH2:14][NH:15][C:16]2[C:21]([N+:22]([O-:24])=[O:23])=[CH:20][N:19]=[C:18](Cl)[N:17]=2)[CH2:10][CH2:9]1)([CH3:4])([CH3:3])[CH3:2].CCN(CC)CC.[N:34]1([C:40]2[CH:41]=[C:42]([CH:45]=[CH:46][CH:47]=2)[CH2:43][NH2:44])[CH2:39][CH2:38][CH2:37][CH2:36][CH2:35]1.CCO>C(Cl)Cl.CC(N(C)C)=O>[C:1]([O:5][C:6](=[O:26])[NH:7][CH:8]1[CH2:13][CH2:12][CH:11]([CH2:14][NH:15][C:16]2[C:21]([N+:22]([O-:24])=[O:23])=[CH:20][N:19]=[C:18]([NH:44][CH2:43][C:42]3[CH:45]=[CH:46][CH:47]=[C:40]([N:34]4[CH2:39][CH2:38][CH2:37][CH2:36][CH2:35]4)[CH:41]=3)[N:17]=2)[CH2:10][CH2:9]1)([CH3:4])([CH3:3])[CH3:2]참가 물질
7
반응물 4
생성물 1
시약·촉매·용매 2
실험 절차
{trans-4-[(2-Chloro-5-nitro-pyrimidin-4-ylamino)-methyl]-cyclohexyl}-carbamic acid tert-butyl ester (200 mg, 0.52 mmol) was dissolved in CH2Cl2 (10 mL) and Et3N (0.289 mL, 2.07 mmol) was added. 3-Piperidin-1-yl-benzylamine (197 mg, 1.04 mmol) was dissolved in DMA:EtOH (2 mL, 1:1) and added to the reaction solution. The reaction was stirred at room temperature for 18 h. The volatiles were removed in vacuo and the crude was purified via flash chromatography (SiO2, 25-50% EtOAc:Hexanes then 5% MeOH:CH2Cl2) to afford 176 mg (63%) of (4-{[5-nitro-2-(3-piperidin-1-yl-benzylamino)-pyrimidin-4-ylamino]-methyl}-cyclohexyl)-carbamic acid tert-butyl ester
후처리
- customThe volatiles were removed in vacuo
- customthe crude was purified via flash chromatography (SiO2, 25-50% EtOAc
출처 및 근거
- ORD 기록
- ord-cc85408cc8fa43c4b3e43322edef0a6a
- 출처 데이터셋
- uspto-grants-2009_10
- 특허 번호
- US07601714B2
반응 노트
불러오는 중…